THOMAS SHOAF: Open Payments
NPI 1396031027 · RICHARDSON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$29,975 in 157 payments from 22 companies in 2025. Trend: 2023 $2,619 · 2024 $1,941 · 2025 $29,975
Debt forgiveness: $27,090Food & beverage: $2,885
| Company | Payments | Amount |
|---|---|---|
| Neuronetics, Inc. | 1 | $27,090 |
| Vanda Pharmaceuticals Inc. | 22 | $557 |
| Neurocrine BioSciences, Inc. | 18 | $310 |
| ABBVIE INC. | 24 | $303 |
| Alkermes, Inc. | 15 | $202 |
| Validus Pharmaceuticals LLC | 9 | $195 |
| Otsuka America Pharmaceutical, Inc. | 10 | $194 |
| E.R. Squibb & Sons, L.L.C. | 11 | $183 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $163 |
| Teva Pharmaceuticals USA, Inc. | 7 | $160 |
Products named: NEUROSTAR TMS THERAPY SYSTEM, FANAPT, INGREZZA, VRAYLAR, REXULTI, COBENFY, CAPLYTA, Azstarys.
Industry payments across TX — which companies pay providers there.
